Leerink Partnrs Forecasts Higher Earnings for AnaptysBio

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Research analysts at Leerink Partnrs lifted their FY2024 earnings estimates for shares of AnaptysBio in a note issued to investors on Tuesday, November 5th. Leerink Partnrs analyst D. Risinger now forecasts that the biotechnology company will post earnings of ($5.76) per share for the year, up from their prior estimate of ($6.48). The consensus estimate for AnaptysBio's current full-year earnings is ($6.84) per share. Leerink Partnrs also issued estimates for AnaptysBio's Q4 2024 earnings at ($1.30) EPS, Q1 2025 earnings at ($1.88) EPS, Q2 2025 earnings at ($1.69) EPS, Q3 2025 earnings at ($1.75) EPS, Q4 2025 earnings at ($1.07) EPS, FY2025 earnings at ($6.01) EPS, FY2026 earnings at ($4.16) EPS, FY2027 earnings at ($3.41) EPS and FY2028 earnings at ($2.87) EPS.

Other equities research analysts have also recently issued reports about the stock. UBS Group boosted their price objective on shares of AnaptysBio from $23.00 to $33.00 and gave the company a "neutral" rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. boosted their price objective on shares of AnaptysBio from $69.00 to $75.00 and gave the company an "overweight" rating in a research report on Wednesday, August 7th. Wedbush reaffirmed an "outperform" rating and issued a $42.00 price objective on shares of AnaptysBio in a research report on Wednesday. Guggenheim boosted their price objective on shares of AnaptysBio from $75.00 to $90.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Finally, Truist Financial boosted their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the company a "hold" rating in a research report on Thursday, August 15th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $55.45.

AnaptysBio Stock Down 0.8 %

ANAB traded down $0.18 during trading on Friday, hitting $21.31. The company had a trading volume of 416,110 shares, compared to its average volume of 348,299. The company has a market capitalization of $584.53 million, a PE ratio of -3.36 and a beta of -0.24. AnaptysBio has a one year low of $13.36 and a one year high of $41.31. The firm's 50-day moving average price is $32.66 and its 200 day moving average price is $29.84.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping analysts' consensus estimates of ($1.72) by $0.58. The company had revenue of $30.02 million for the quarter, compared to analysts' expectations of $7.92 million. AnaptysBio had a negative net margin of 558.25% and a negative return on equity of 255.68%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jennison Associates LLC acquired a new position in shares of AnaptysBio during the 3rd quarter worth approximately $8,874,000. Victory Capital Management Inc. boosted its stake in shares of AnaptysBio by 677.9% in the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company's stock valued at $7,948,000 after buying an additional 206,750 shares during the period. GSA Capital Partners LLP acquired a new stake in AnaptysBio during the third quarter worth approximately $574,000. China Universal Asset Management Co. Ltd. increased its stake in AnaptysBio by 81.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company's stock worth $195,000 after acquiring an additional 2,600 shares during the period. Finally, Values First Advisors Inc. bought a new position in AnaptysBio during the 3rd quarter worth $49,000.

Insiders Place Their Bets

In related news, CFO Dennis Mulroy sold 12,220 shares of the company's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the transaction, the chief financial officer now owns 4,744 shares in the company, valued at approximately $189,333.04. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, major shareholder Ecor1 Capital, Llc purchased 273,972 shares of the firm's stock in a transaction that occurred on Wednesday, August 14th. The shares were acquired at an average price of $36.50 per share, for a total transaction of $9,999,978.00. Following the purchase, the insider now owns 7,794,996 shares in the company, valued at approximately $284,517,354. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Dennis Mulroy sold 12,220 shares of the company's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares in the company, valued at approximately $189,333.04. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,440 shares of company stock valued at $892,936 in the last three months. 33.70% of the stock is currently owned by corporate insiders.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.